Funding opportunities

• Supports a small number of exceptional clinical researchers to promote their development as early-stage independent investigators
• Provides 5-7 years of support as an independent principal investigator in the NIH Intramural Research Program
• Followed by up to 3 years of funding at an extramural research institution

For more information: https://irp.nih.gov/careers/faculty-level-scientific-careers/lasker-clinical-research-scholars

Deadline: August 25, 2023

• In 15^th year with over 100 positions filled
• Up to ten positions per year
• Tenure-track positions within the NIH Intramural Research Program
• Broad range of scientific disciplines
‍
For more information: https://irp.nih.gov/careers/faculty-level-scientific-careers/stadtman-tenure-track-investigators

Deadline: September 30, 2023

This notice of funding opportunity provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic andpharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this opportunity is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug application development or progression toclinical trials in the case of repurposing or repositioning. 
‍
The NIH supports research on a broad range of diseases that are defined as rare; that is, diseases affecting fewer than 200,000 individualsin the United States. While individually, each rare disease affects a limited number of individuals, when viewed collectively, rare diseases represent a significant unmet medical need. Approximately 30 million people in the United States are living with one of the estimated 10,000 rare diseases; many of which affect children and are serious or life-threatening. Despite advances in our understanding of the mechanisms of many rare diseases, and large investments by pharmaceutical and biotech industries, effective treatments are available for fewer than 5% of diseases.

This opportunity solicits applications that propose to conduct efficacy studies in an established rare disease preclinical model to demonstrate proof of concept that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic(PD) and pharmacokinetic (PK) studies would be supported.

For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-23-016.html

Deadline: October 2, 2023